InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-8.6%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Hassan Fred, Director. Officer active across 4 companies, notably BridgeBio Pharma, Inc.. In total, 14 filings have been published. Split: 3 buys · 0 sell. Total volume traded: €1.4m. Activity tracked since 29 December 2021. The latest transaction was disclosed on 13 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations14 total
3,990 sharesCommon StockSEC:0001470831-26-000629:0
36,206 shares@ US$1.745.1% of flowCommon StockSEC:0000950103-25-003518:0
8,067 sharesCommon StockSEC:0001493152-24-040899:0
44,055 shares@ US$1.435.1% of flowCommon StockSEC:0000950103-24-003955:0
106,837 sharesCommon StockSEC:0000950103-24-003746:0
570,345 shares@ US$1.7580.7% of flowCommon StockSEC:0000950103-23-012143:0
Ideal exit: 10 May 2024 (T+270)
2,123 sharesCommon StockSEC:0000899243-23-015758:0
2,123 shares0Common StockSEC:0001209191-23-031175:0
48,290 shares@ US$1.174.7% of flowCommon StockSEC:0000950103-23-004007:0
61,576 sharesCommon StockSEC:0000950103-23-003029:0
16,212 sharesCommon StockSEC:0000950103-22-005404:0
27,832 shares@ US$2.030.0032% mcap100.0% of flowCommon StockSEC:0000950103-22-003221:0
19,300 shares@ US$14.16530.0016% mcap50.0% of flowCommon StockSEC:0000899243-22-000176:0
Ideal exit: 25 Sept 2022 (T+270)
19,300 shares@ US$14.165350.0% of flowCommon StockSEC:0000899243-22-000176
Ideal exit: 25 Sept 2022 (T+270)
14 of 14 declarations
About Hassan Fred
Fred Hassan serves as a Board Member at BridgeBio Pharma, Inc. and Precigen, Inc. In this role, he participates in the governance of these companies and strategic decision-making. Fred Hassan brings expertise in biopharmaceuticals and management, contributing to the direction of BridgeBio and Precigen in the healthcare sector. His commitment to best governance practices is essential for the success of these companies.
